Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Net income | -$63.1M | -$25.2M |
| EPS (diluted) | -$176.15 | -$3.13 |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$53.1M | -$35.2M |
| Capital expenditures | $769K | $52.0K |
| Free cash flow | -$53.8M | -$35.3M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $23.0M | $250M |
| Total assets | $33.5M | $313M |
| Total liabilities | $13.8M | $11.6M |
| Shareholders' equity | -$94.6M | $301M |
| Retained earnings | -$104M | -$130M |
| Shares (wtd avg diluted) | 358K | 8.05M |
Every figure is extracted from LB PHARMACEUTICALS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.